| Title |
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial
|
|---|---|
| Published in |
Clinical Cancer Research, May 2020
|
| DOI | 10.1158/1078-0432.ccr-19-4000 |
| Pubmed ID | |
| Authors |
Ming Lu, Panpan Zhang, Yanqiao Zhang, Zhongwu Li, Jifang Gong, Jie Li, Jian Li, Yan Li, Xiaotian Zhang, Zhihao Lu, Xicheng Wang, Jun Zhou, Zhi Peng, Weifeng Wang, Hui Feng, Hai Wu, Sheng Yao, Lin Shen |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 26% |
| Spain | 2 | 11% |
| Turkey | 1 | 5% |
| United Kingdom | 1 | 5% |
| India | 1 | 5% |
| Peru | 1 | 5% |
| Mexico | 1 | 5% |
| Unknown | 7 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 58% |
| Practitioners (doctors, other healthcare professionals) | 4 | 21% |
| Scientists | 3 | 16% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 13% |
| Other | 3 | 10% |
| Student > Bachelor | 3 | 10% |
| Lecturer | 2 | 7% |
| Student > Doctoral Student | 1 | 3% |
| Other | 5 | 17% |
| Unknown | 12 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 43% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Agricultural and Biological Sciences | 2 | 7% |
| Nursing and Health Professions | 1 | 3% |
| Chemistry | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 11 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 137. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2021.
All research outputs
#267,680
of 23,511,526 outputs
Outputs from Clinical Cancer Research
#119
of 12,754 outputs
Outputs of similar age
#8,844
of 389,140 outputs
Outputs of similar age from Clinical Cancer Research
#4
of 183 outputs
Altmetric has tracked 23,511,526 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,754 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 389,140 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 183 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.